NervGen Pharma Corp. (NGEN)
| Market Cap | 250.53M +31.6% |
| Revenue (ttm) | n/a |
| Net Income | -43.63M |
| EPS | -0.64 |
| Shares Out | 107.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 920,469 |
| Open | 2.310 |
| Previous Close | 2.320 |
| Day's Range | 2.275 - 2.395 |
| 52-Week Range | 1.580 - 6.300 |
| Beta | 0.73 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About NGEN
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Co... [Read more]
News
NervGen Pharma reports Q2 EPS (C$0.37) vs. (C$0.13) last year
“With FDA alignment and funding to support RESTORE now in place, we have expanded our organization with experienced professionals who understand the operational demands of late-stage clinical developm...
NervGen Pharma Earnings release: Q2 2026
NervGen Pharma released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal...
NervGen Pharma price target lowered to $15 from $18 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on NervGen Pharma (NGEN) to $15 from $18 and keeps a Buy rating on the shares. The firm cites equity…
NervGen Pharma initiated with an Outperform at Leerink
Leerink analyst Marc Goodman initiated coverage of NervGen Pharma (NGEN) with an Outperform rating and $10 price target
NervGen Pharma initiated with a Buy at TD Cowen
TD Cowen initiated coverage of NervGen Pharma (NGEN) with a Buy rating and no price target The company is advancing treatments of neurotraumatic and neurologic conditions, the analyst tells investors…
NervGen Pharma files $250M mixed securities shelf
09:28 EDT NervGen Pharma (NGEN) files $250M mixed securities shelf
NervGen Pharma Registration statement: Registration filing
NervGen Pharma filed a registration statement on May 26, 2026, providing details about a securities offering with the SEC.
NervGen Pharma announces biomechanical gait analyses on recovery with NVG-291
NervGen Pharma (NGEN) announced positive independent, blinded biomechanical gait analyses demonstrating genuine neural recovery with NVG-291 in the Phase 1b/2a CONNECT SCI study. Key highlights: NVG-2...
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neu...
NervGen Pharma 24M share Spot Secondary priced at $2.50
Leerink and TD Cowen acted as joint book running managers for the offering.
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neu...
NervGen Pharma secondary being re-offered at $2.50 per share
Leerink Partners and TD Cowen are acting as joint bookrunning managers for the offering.
NervGen Pharma announces common share offering, no amount given
NervGen Pharma (NGEN) Corp. announced that it has commenced an underwritten public offering of common shares and accompanying warrants to purchase common shares and, in lieu of common shares to…
NervGen Announces Proposed Public Offering of Securities
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neu...
NervGen Pharma Slides: Corporate presentation
NervGen Pharma has posted slides in relation to its latest quarterly earnings report, which was published on May 21, 2026.
NervGen Pharma reports Q1 EPS (2c), consensus (7c)
“With the achievement of FDA alignment on the study parameters of RESTORE, our registrational study of NVG-291 in chronic tetraplegia, NervGen is now firmly in execution mode,” said Adam Rogers,…
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
VANCOUVER, British Columbia, May 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neu...
NervGen Pharma Earnings release: Q1 2026
NervGen Pharma released its Q1 2026 earnings on May 18, 2026, summarizing the period's financial results.
NervGen Pharma appoints Keith Vendola as CFO
NervGen announced the appointment of Keith Vendola as CFO, effective immediately. Vendola will lead the company’s financial strategy and operations, including capital markets activity, financial plann...
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class n...
NervGen Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of NervGen Pharma (NGEN) with a Buy rating and $18 price target The company is developing therapies for devastating neurological condition...
NervGen Pharma Transcript: HCW Home with NervGen Conference
NVG-291, a peptide therapy for chronic cervical spinal cord injury, showed significant functional and quality-of-life improvements in the CONNECT trial, with a strong safety profile. The upcoming RESTORE phase III trial is designed for regulatory approval, targeting a large unmet need and leveraging a cost-efficient, scalable approach.
NervGen Pharma initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of NervGen Pharma (NGEN) with a Buy rating and $18 price target The company’s lead clinical candidate, NVG-291, is about to enter a pivotal trial for…
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class n...